AR040075A2 - 1h-pirimido[4,5-d]pirimidin-2-onas y sales, composiciones farmaceuticas y uso para la fabricacion de un medicamento - Google Patents
1h-pirimido[4,5-d]pirimidin-2-onas y sales, composiciones farmaceuticas y uso para la fabricacion de un medicamentoInfo
- Publication number
- AR040075A2 AR040075A2 ARP030101602A ARP030101602A AR040075A2 AR 040075 A2 AR040075 A2 AR 040075A2 AR P030101602 A ARP030101602 A AR P030101602A AR P030101602 A ARP030101602 A AR P030101602A AR 040075 A2 AR040075 A2 AR 040075A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- aryl
- ring
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
1H-pirimido[4,5-d]pirimidin-2-ona que tiene la siguientes fórmula (1); donde R1, X y R3 son seleccionados respectivamente de los grupos a) R11, X1, y R13; b) R31, X3 y R33; y c) R51, X5 y R53; a) donde: R11 es un anillo arilo o heteroarilo, cuyo anillo está opcionalmente sustituido; R12 es hidrógeno, alquilo C1-10, cicloalquilo C3-7, cicloalquil(C3-7)-alquilo(C1-10), arilo, aril-alquilo C1-10, heteroarilo, heteroaril-alquilo C1-10, heterocíclico, o un resto heterociclil-alquilo C1-10; y en el que cada uno de estos restos, excluyendo hidrógeno, está opcionalmente sustituido; R13 es un resto alquilo C1-10, cicloalquilo C3-7, cicloalquil(C3-7)-alquilo(C1-10), aril-alquilo C1-10, heteroaril-alquilo C1-10, o heterociclil-alquilo C1-10; y en el que cada uno de estos restos están opcionalmente sustituidos; X1 es R12, OR12, S(O)mR12 o (CH2)nNR14R15, o (CH2)nNR12R14; n es 0 o un número entero que tiene un valor de 1 a 10; m es 0 o un número entero que tiene un valor de 1 ó 2; R14 y R15 se seleccionan cada uno independientemente de hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, o un aril-alquilo C1-4 opcionalmente sustituido, o R14 y R15 junto con el nitrógeno al que están unidos forman un anillo heterocíclico de 5 a 7 miembros, cuyo anillo contiene opcionalmente un heteroátomo adicional seleccionado de oxígeno, azufre o NR19; R16 es hidrógeno, alquilo C1-10, cicloalquilo C3-7, heterociclilo, heterociclil-alquilo C1-10, arilo, aril-alquilo C1-10, heteroarilo o un resto heteroaril-alquilo C1-10; y en el que cada uno de estos restos, excluyendo hidrógeno, puede estar opcionalmente sustituido; R19 es hidrógeno, C(Z)R16, alquilo C1-10 opcionalmente sustituido, arilo opcionalmente sustituido, o aril-alquilo C1-4 opcionalmente sustituido, Z es oxígeno o azufre; o una de sus sales farmacéuticamente aceptables; b) donde: R31 es un arilo, o un anillo heteroarilo, cuyo anillo está opcionalmente sustituido; R32 es un anillo heterocíclico o heterocíclico-alquilo C1-10, cuyo anillo está opcionalmente sustituido; R32' es un anillo heterocíclico, heterocíclico-alquilo C1-10, arilo, o heteroarilo, cuyo anillo está opcionalmente sustituido; R33 es un anillo arilo o heteroarilo, cuyo anillo está opcionalmente sustituido; X3 es R32', OR32, S(O)mR32 o (CH2)nNR34R35, o (CH2)nNR32R34; con la condición de que, cuando X3 es (CH2)nNR34R35, entonces R34R35 debe formar el anillo ciclado opcionalmente sustituido que comprende opcionalmente un resto oxígeno, azufre o nitrógeno, n es 0 o un número entero que tiene un valor de 1 a 10; m es 0 o un número que tiene un valor de 1 ó 2; R34 y R35 se seleccionan independientemente de hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, o aril-alquilo C1-4 opcionalmente sustituido; o R34 y R35 junto con el nitrógeno al que están unidos un anillo heterocíclico de 5 a 7 miembros cuyo anillo contiene opcionalmente un heteroátomo adicional seleccionado de oxígeno, azufre o NR39, y cuyo anillo está opcionalmente sustituidos; R36 es hidrógeno, alquilo C1-10, cicloalquilo C3-7, heterocíclico, heterociclil-alquilo C1-10, arilo, aril-alquilo C1-10, heteroarilo o un resto heteroaril-alquilo C1-10; y en el que cada uno de estos restos, excluyendo hidrógeno, está opcionalmente sustituido; R39 es hidrógeno, C(Z)R36, alquilo C1-10 opcionalmente sustituido, arilo opcionalmente sustituido, o aril-alquilo C1-4 opcionalmente sustituido; Z es oxígeno o azufre; o una de sus sales farmacéuticamente aceptables; c) donde: X5 es R52, OR52, S(O)mR52 o (CH2)nNR54R55, o (CH2)nR52R54; n es 0 o un número entero que tiene un valor de 1 a 10; m es 0 o un número entero que tiene un valor de 1 ó 2; y R51 es un anillo arilo opcionalmente sustituido; R52 es hidrógeno, alquilo C1-10, cicloalquilo C3-7, cicloalquil(C3-7)-alquilo, arilo, aril-alquilo C1-10,. heteroarilo, heteroaril-alquilo C1-10, resto heterocíclico, o un resto heterociclil-alquilo C1-10; y en el que cada uno de estos restos, excluyendo hidrógeno está opcionalmente sustituido; R53 es un anillo arilo opcionalmente sustituido; R54 y R55 se seleccionan cada uno independientemente de hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, o aril-alquilo C1-4 opcionalmente sustituido, o R54 y R55 junto con el nitrógeno al que están unidos forman un anillo heterocíclico de 5 a 7 miembros cuyo anillo contiene opcionalmente un heteroátomo adicional seleccionado de oxígeno, azufre o NR59; R56 es hidrógeno, alquilo C1-10, cicloalquilo C3-7, heterociclilo, heteroaril-alquilo C1-10, arilo, aril-alquilo C1-10, heteroarilo o un resto heteroaril-alquilo C1-10; y en el que cada uno de estos restos, excluyendo hidrógeno, puede estar opcionalmente sustituido; R59 es hidrógeno, C(Z)R56, alquilo C1-10 opcionalmente sustituido, arilo opcionalmente sustituido o un aril-alquilo C1-4 opcionalmente sustituido; Z es oxígeno azufre o una de sus sales farmacéuticamente aceptables. Composiciones farmacéuticas que comprenden el compuesto o una sal farmacéuticamente aceptable del mismo. Uso del compuesto o de una sal farmacéuticamente aceptable del mismo, para la fabricación de un medicamento para el tratamiento, incluyendo la profilaxis, de una enfermedad mediada por CSBP / RK / p38 quinasa en un mamífero. Estas enfermedades incluyen afecciones crónicas como la retinopatía diabética y degeneración muscular; infecciones de las vías respiratorias causadas por virus; neumonía inducida por el virus de la influenza y resfriado común.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18641900P | 2000-03-02 | 2000-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040075A2 true AR040075A2 (es) | 2005-03-16 |
Family
ID=22684876
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100940A AR030053A1 (es) | 2000-03-02 | 2001-02-28 | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
| ARP030101602A AR040075A2 (es) | 2000-03-02 | 2003-05-07 | 1h-pirimido[4,5-d]pirimidin-2-onas y sales, composiciones farmaceuticas y uso para la fabricacion de un medicamento |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010100940A AR030053A1 (es) | 2000-03-02 | 2001-02-28 | 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1265900B1 (es) |
| JP (1) | JP2003525295A (es) |
| KR (1) | KR100806978B1 (es) |
| CN (1) | CN100482664C (es) |
| AR (2) | AR030053A1 (es) |
| AT (1) | ATE362473T1 (es) |
| AU (2) | AU2001239992B2 (es) |
| BR (1) | BR0108715A (es) |
| CA (1) | CA2402092C (es) |
| CY (1) | CY1106816T1 (es) |
| CZ (1) | CZ20022933A3 (es) |
| DE (1) | DE60128457T2 (es) |
| DK (1) | DK1265900T3 (es) |
| ES (1) | ES2287107T3 (es) |
| HK (1) | HK1052932A1 (es) |
| HU (1) | HUP0204431A3 (es) |
| IL (3) | IL151426A0 (es) |
| MX (1) | MXPA02008588A (es) |
| MY (1) | MY141144A (es) |
| NO (1) | NO326409B1 (es) |
| NZ (1) | NZ520914A (es) |
| PL (1) | PL358280A1 (es) |
| PT (1) | PT1265900E (es) |
| TW (1) | TWI290926B (es) |
| WO (1) | WO2001064679A1 (es) |
| ZA (1) | ZA200207017B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID27589A (id) | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
| CZ20031125A3 (cs) * | 2000-10-23 | 2003-10-15 | Smithkline Beecham Corporation | Nové sloučeniny |
| CA2431904A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| GB0124848D0 (en) | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
| MXPA04007838A (es) | 2002-02-12 | 2004-10-15 | Smithkline Beecham Corp | Derivados de nicotamida utiles como inhibidores p38. |
| ES2345096T3 (es) * | 2002-02-13 | 2010-09-15 | F. Hoffmann-La Roche Ag | Nuevos derivados de piridina y pirimidina. |
| PL373339A1 (en) * | 2002-04-19 | 2005-08-22 | Smithkline Beecham Corporation | Novel compounds |
| GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| US7196090B2 (en) | 2002-07-25 | 2007-03-27 | Warner-Lambert Company | Kinase inhibitors |
| GB0218800D0 (en) * | 2002-08-13 | 2002-09-18 | Celltech R&D Ltd | Chemical compounds |
| US7084270B2 (en) * | 2002-08-14 | 2006-08-01 | Hoffman-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US7268139B2 (en) | 2002-08-29 | 2007-09-11 | Scios, Inc. | Methods of promoting osteogenesis |
| US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
| US7384937B2 (en) | 2002-11-06 | 2008-06-10 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| EP1615928A1 (en) | 2003-04-10 | 2006-01-18 | F.Hoffmann-La Roche Ag | Pyrimido compounds |
| US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| PT1699800E (pt) * | 2003-12-23 | 2010-04-12 | Novartis Ag | Inibidores de quinase p-38 heterocíclicos bicíclicos |
| WO2006065703A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| JP5201817B2 (ja) * | 2005-10-28 | 2013-06-05 | 大塚製薬株式会社 | 医薬組成物 |
| EP2031965A4 (en) * | 2006-06-16 | 2010-06-30 | Glaxo Group Ltd | NEW COMPOUNDS |
| JP2009542818A (ja) * | 2006-06-16 | 2009-12-03 | グラクソ グループ リミテッド | 新規化合物 |
| KR101040394B1 (ko) * | 2010-05-18 | 2011-06-09 | (주)이성산업 | 역화 방지 기능을 갖는 야외용 가스 히터 |
| CN102816162B (zh) * | 2011-06-10 | 2016-04-27 | 中国科学院广州生物医药与健康研究院 | 嘧啶并嘧啶酮类化合物及其药用组合物和应用 |
| CN111793068A (zh) | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| US9321786B2 (en) | 2013-03-15 | 2016-04-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP3943087A1 (en) | 2013-03-15 | 2022-01-26 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| WO2015055071A1 (zh) * | 2013-10-16 | 2015-04-23 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| US20190060286A1 (en) | 2016-02-29 | 2019-02-28 | University Of Florida Research Foundation, Incorpo | Chemotherapeutic Methods |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| CA3128468A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60226882A (ja) * | 1984-04-24 | 1985-11-12 | Nippon Zoki Pharmaceut Co Ltd | 新規ピリミドピリミジン誘導体 |
| KR20000029843A (ko) * | 1996-08-06 | 2000-05-25 | 디. 제이. 우드;스피겔 알렌 제이 | 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체 |
| ID27589A (id) * | 1998-05-26 | 2001-04-12 | Warner Lambert Comapny | Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular |
| JP2002517486A (ja) * | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| WO2000024744A1 (en) * | 1998-10-23 | 2000-05-04 | F. Hoffmann-La Roche Ag | Bicyclic nitrogen heterocycles |
-
2001
- 2001-02-28 MY MYPI20010900A patent/MY141144A/en unknown
- 2001-02-28 AR ARP010100940A patent/AR030053A1/es unknown
- 2001-03-02 PT PT01914625T patent/PT1265900E/pt unknown
- 2001-03-02 JP JP2001564176A patent/JP2003525295A/ja active Pending
- 2001-03-02 DE DE60128457T patent/DE60128457T2/de not_active Expired - Lifetime
- 2001-03-02 DK DK01914625T patent/DK1265900T3/da active
- 2001-03-02 PL PL01358280A patent/PL358280A1/xx not_active Application Discontinuation
- 2001-03-02 CA CA2402092A patent/CA2402092C/en not_active Expired - Fee Related
- 2001-03-02 TW TW090104783A patent/TWI290926B/zh not_active IP Right Cessation
- 2001-03-02 EP EP01914625A patent/EP1265900B1/en not_active Expired - Lifetime
- 2001-03-02 KR KR1020027011408A patent/KR100806978B1/ko not_active IP Right Cessation
- 2001-03-02 CZ CZ20022933A patent/CZ20022933A3/cs unknown
- 2001-03-02 CN CNB018076866A patent/CN100482664C/zh not_active Expired - Fee Related
- 2001-03-02 AU AU2001239992A patent/AU2001239992B2/en not_active Ceased
- 2001-03-02 WO PCT/US2001/006688 patent/WO2001064679A1/en active Application Filing
- 2001-03-02 NZ NZ520914A patent/NZ520914A/en not_active IP Right Cessation
- 2001-03-02 AU AU3999201A patent/AU3999201A/xx active Pending
- 2001-03-02 BR BR0108715-0A patent/BR0108715A/pt not_active Application Discontinuation
- 2001-03-02 AT AT01914625T patent/ATE362473T1/de active
- 2001-03-02 IL IL15142601A patent/IL151426A0/xx active IP Right Grant
- 2001-03-02 MX MXPA02008588A patent/MXPA02008588A/es active IP Right Grant
- 2001-03-02 ES ES01914625T patent/ES2287107T3/es not_active Expired - Lifetime
- 2001-03-02 HU HU0204431A patent/HUP0204431A3/hu unknown
-
2002
- 2002-08-22 IL IL151426A patent/IL151426A/en not_active IP Right Cessation
- 2002-08-30 NO NO20024134A patent/NO326409B1/no not_active IP Right Cessation
- 2002-09-02 ZA ZA200207017A patent/ZA200207017B/en unknown
-
2003
- 2003-05-07 AR ARP030101602A patent/AR040075A2/es unknown
- 2003-05-27 HK HK03103782A patent/HK1052932A1/xx not_active IP Right Cessation
-
2007
- 2007-08-13 CY CY20071101080T patent/CY1106816T1/el unknown
-
2008
- 2008-02-28 IL IL189865A patent/IL189865A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040075A2 (es) | 1h-pirimido[4,5-d]pirimidin-2-onas y sales, composiciones farmaceuticas y uso para la fabricacion de un medicamento | |
| ES2657687T3 (es) | Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales | |
| ES2707885T3 (es) | Alquilpirimidinderivados para el tratamiento de infecciones víricas y otras enfermedades | |
| KR102488479B1 (ko) | 인플루엔자 바이러스 감염에 사용하기 위한 인돌 | |
| UY27333A1 (es) | Nucleótidos 4` sustituidos | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
| AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
| UY28084A1 (es) | Derivados antivirales de nucleosidos | |
| CY1116103T1 (el) | Υποκατεστημενα παραγωγα 1,2,3,4-τετραϋδροϊσοκινολινης | |
| ATE504579T1 (de) | Antivirale mittel | |
| UY28578A1 (es) | Derivados de amida | |
| WO2008132138A9 (en) | AMINOPYRIMIDINE DERIVATIVES DISUBSTITUTED IN 4 AND 6 | |
| NO20074781L (no) | 4-Oksokinazolin-3-ylbenzamidderivater for behandling av cytokinsykdommer | |
| UY29301A1 (es) | Derivados amida | |
| AR035669A1 (es) | Imidazoquinolinas y 6,7,8,9-tetrahidroimidazoquinolinas, composiciones que las comprenden, y usos de dichos compuestos en la preparacion de medicamentos | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| UY29823A1 (es) | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones | |
| AR125401A1 (es) | Compuestos heterocíclicos novedosos | |
| CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| ECSP088257A (es) | Derivados de amida | |
| EA200702637A1 (ru) | Производные пурина | |
| UY26720A1 (es) | Derivados del pirrol | |
| DK0527081T3 (da) | Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |